Skip to content

Earnings call

Acutaas Chemicals Q2 FY26 earnings call

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Ongoing CDMO projects are progressing in line with expectations and are expected to start contributing by end of FY '26, subject to regulatory approvals. Pilot plant capex is proceeding as planned and is expected to be completed by Q3 FY '26. Q2 FY '26 revenue grew by 24.1% year-on-year to INR306.2 crores, primarily driven by the Advanced Pharmaceutical Intermediates segment, while the Specialty Chemicals business continued to demonstrate stable performance. The company has more than 50% to 80% market share for most of its top products against any competitor. Net cash and cash equivalents were INR240.6 crores as on 30th September 2025.

The numbers management gave

Results

  • Q2 FY '26 revenue grew by 24.1% year-on-year to INR306.2 crores, primarily driven by the Advanced Pharmaceutical Intermediates segment, while the Specialty Chemicals business continued to demonstrate stable performance.
    Show source
    Our Q2 FY '26 revenue grew by 24.1% year- on-year to INR306.2 crores.
  • Pharmaceutical Intermediates segment delivered revenue of INR262.6 crores in Q2 FY '26, up 27.1% year-on-year, primarily driven by CDMO business and supported by contribution from the core Advanced Pharmaceutical Intermediates segment.
    Show source
    This segment delivered a robust performance with revenue of INR262.6 crores in Q2 FY '26, reflecting a strong year-on-year growth of 27.1%.
  • Specialty Chemicals segment revenue was INR43.6 crores in Q2 FY '26, up 7.3% year-on-year.
    Show source
    Revenue of this segment stood at INR43.6 crores during the quarter, a steady growth of 7.3% year-on-year.
  • Revenue from operations was INR306.2 crores in Q2 FY '26, up 24.1% year-on-year; gross profit was INR170.7 crores, up 59.3% compared with the same period last year.
    Show source
    Revenue from operations for the quarter reached INR306.2 crores, representing Page 4 of 17 Acutaas Chemicals Limited October 17, 2025 24.1% growth Y-o-Y. Gross profit for the quarter was INR170.7 crores, reflecting 59.3% increase compared to the same period last year.
  • Gross margin expanded by 1,232 basis points year-on-year to 55.8% in Q2 FY '26, driven by improved product mix and operational efficiencies.
    Show source
    The gross margin expanded by 1,232 basis points Y-o-Y to 55.8%.
  • EBITDA was INR95.3 crores in Q2 FY '26, almost double the EBITDA of the same period last year.
    Show source
    EBITDA for the quarter was INR95.3 crores, which grew almost 2x compared to the EBITDA of same period last year.
Show 12 more statements

Results

  • EBITDA margin was 31.1% in Q2 FY '26, up 1,130 basis points year-on-year, driven by gross margin expansion and operating leverage.
    Show source
    EBITDA margins were at 31.1%, up 1,130 basis points Y-o-Y. EBITDA margin was driven by expansion in gross margin as well as operating leverage.
  • PAT was INR71.9 crores in Q2 FY '26, up 91.3% year-on-year, and PAT margin was 23.5%, up 824 basis points year-on-year.
    Show source
    PAT for the quarter was INR71.9 crores, up 91.3% Y-o-Y. PAT margins for the quarter were 23.5%, which show an expansion of 824 basis points Y-o-Y. Moving on the H1 FY '26 performance.
  • Revenue from operations was INR513.4 crores in H1 FY '26, up 21.3% year-on-year.
    Show source
    Revenue from operations for the first half of the year reached INR513.4 crores, representing 21.3% increase year-on-year.
  • EBITDA was INR146.2 crores in H1 FY '26, up 86.4% year-on-year, and PAT was INR115.9 crores, more than double compared with the same period last year.
    Show source
    EBITDA for the H1 FY '26 was INR146.2 crores, up 86.4% Y-o-Y. PAT for H1 FY '26 was at INR115.9 crores, which more than doubled compared to the same period last year.
  • Working capital was 100 days in Q2 FY '26, an improvement of 28 days compared with Q1 FY '26.
    Show source
    Our working capital for the quarter improved to 100 days, which is 28 days improvement compared to Q1 FY '26.
  • The company improved its margins at an operational level by more than 2.5% through operational efficiency and contribution from its commissioned solar power plant project.
    Show source
    Apart from that, we have also improved our margins at an operational level by more than 2.5%, and that is because of operational efficiency and the contribution from our solar power plant project, which is now commissioned.
  • The company brought its receivables to 87 days for this quarter through improved collection and its efforts.
    Show source
    With improved collection and our effort, we are able to bring it to 87 days for this quarter.
  • Net cash and cash equivalents were INR270 crores in Q1 FY '26.
    Show source
    Improved working capital with robust business performance led to strong generation of cash from operations of INR136.5 crores during H1 FY '26.
  • Commodity chemical subsegment recorded year-on-year and sequential growth, led by higher volume and stable pricing.
    Show source
    Our commodity chemical subsegment recorded a strong growth both on year-on-year and sequential basis, led by higher volume as well as stable pricing.
  • Commodity chemical subsegment growth was partly offset by softer performance in Baba Fine Chemicals business.
    Show source
    However, this was partly offset by softer performance in Baba Fine Chemicals business.
  • Margin expansion is due to product mix, operational efficiency and cost improvement measures over the year, not commissioning of the new block.
    Show source
    As I mentioned, the margin expansion is a function of product mix as well as the operational efficiency as well as the cost improvement measure what we have done over the year.

Money and capital

  • Net cash and cash equivalents were INR240.6 crores as on 30th September 2025.
    Show source
    Net cash and cash equivalents were at INR240.6 crores as on 30th September 2025.

What it expects ahead

What management expects

  • Ongoing CDMO projects are progressing in line with expectations and are expected to start contributing by end of FY '26, subject to regulatory approvals.
    Show source
    Our ongoing CDMO projects are progressing in line with expectations and expected to start contributing by end of FY '26, subject to regulatory approvals.
  • The company expects around 25% revenue growth and an EBITDA margin in the range of 28% to 30% in FY '26, primarily driven by higher CDMO contribution, product mix, improved profitability in Pharmaceutical Intermediates segment and operational efficiency. Acutaas Chemicals Limited remains confident of delivering around 25% revenue growth for the full year.
    Show source
    To conclude, we are on track to achieve around 25% revenue growth with EBITDA margin expectation to be in the range of 28% to 30% in FY '26.
  • The company expects full-year working capital to be around anything between 95 to 105 days.
    Show source
    For the full year, we believe working capital would be around anything between 95 to 105 days.
  • The company expects an asset turn of around 2.5x generally from all its capex going forward.
    Show source
    In terms of asset turn, we see generally around 2.5x is the asset turn we expect generally from all our capex going forward.
  • The company expects its capex projects to scale up in around 3 years' time.
    Show source
    And around 3 years' time should be the good time by which it should scale up.
  • The company guides that its traditional spec chem business will grow around 10% to 15% and expects it to remain in that territory by the end of this financial year.
    Show source
    Abhishek Patel: So we are guiding that this traditional spec chem business will remain in the territory of around 10% to 15% as a growth for the business.
Show 7 more statements

What management expects

  • The company expects a payback of around 3 to 3.5 years for any project.
    Show source
    Abhishek Patel: For this -- any of the project, we expect the payback to be around 3 to 3.5 year kind of payback.
  • The company expects capacity utilization at Unit 2 Ankleshwar to reach an optimum level in the next 2 years.
    Show source
    And in next 2 years, it should reach to an optimum level.
  • The company expects growth in this business of between 10% and 15% going forward.
    Show source
    Abhishek Patel: So in this business, we are expecting growth in between 10% to 15% only going forward also.
  • A couple of semiconductor chemicals products are expected to move into commercial-scale production through Baba Fine Chemicals.
    Show source
    On semiconductor chemicals, adding to what Naresh bhai mentioned, we have a couple of products that are expected to move into commercial scale production through Baba Fine Chemicals.
  • CDMO segment is growing faster than its traditional business, and is expected to continue to grow faster than its traditional Pharma Intermediates business.
    Show source
    And going forward also, that CDMO business will definitely have a better growth than the traditional Pharma Intermediates business.
  • The company remains confident of delivering around 25% revenue growth for the full year. Replaced by a later filing.
  • The company says it has full visibility of all products and capacity it has planned. Replaced by a later filing.
    Show source
    So we have full visibility of all the products, all the capacity, which we have planned.

What it is building and selling

Projects and capacity

  • H1 capex was INR141 crores, primarily directed towards the Jaghadia site electrolyte additive project and the pilot plant at Sachin site.
    Show source
    Capex for H1 stood at INR141 crores, primarily diverted towards Jaghadia site, focusing on electrolyte additive project and the pilot plant at Sachin site.
  • Pilot plant capex is proceeding as planned and is expected to be completed by Q3 FY '26.
    Show source
    The pilot plant capex is proceeding as per plan and is expected to be completed by Q3 FY '26.
  • Electrolyte additives capex plan is expected to be completed by Q4 FY '26; after commissioning, the plant is expected to start contributing, with a fuller contribution in FY '27 than in Q4 FY '26.
    Show source
    Once that plant gets commissioned because we have full visibility for the products, it will immediately start contributing, maybe not much in the Q4 FY '26 but full year for the FY '27.
  • The company expects its JV in South Korea to be completed in the next calendar year, with commercial production expected to start in H2 FY '27.
    Show source
    Now for the second vertical, which is for the JV in South Korea, we are expecting this to get completed in next calendar year by -- and H2 FY '27 should be the time when it should start the commercial production.
  • 5-megawatt solar project was commissioned in Q2 FY '26 and was partly accounted for in that quarter, out of a total 16 megawatt.
    Show source
    Because the 5-megawatt project was commissioned in this quarter, it was partly accounted in this quarter for 5 megawatt out of the total 16 megawatt.
  • The electrolyte project groundbreaking was done in last month, and the project is expected to start in H2 FY '27, with commercial revenue expected to start from there onwards.
    Show source
    Abhishek Patel: So as we mentioned during our commentary, the groundbreaking for this project was done in last month and project is expected to start in H2 FY '27.
Show 11 more statements

Projects and capacity

  • The company has planned capacity of 2,000 metric ton VC and 2,000 metric ton FEC based on its signed contract with the customer and some demand.
    Show source
    And related to your question of the size of this business, we have planned capacity of 2,000 metric ton VC and 2,000 metric ton FEC based on our signed contract with the customer and some demand.
  • INR250 crores capex plan for FY '26 includes INR40 crores of maintenance capex, around INR180 crores planned for electrolyte additive capex and INR30 crores planned for pilot plant capex; the rest is growth capex.
    Show source
    Abhishek Patel: So out of INR250 crores capex plan for FY '26, INR40 crores we are expecting towards maintenance capex and rest is from the growth -- for the growth capex only. out of which around INR180 crores for the full year was planned for electrolyte additive capex and INR30 crores was planned for pilot plant capex.
  • Over the last 4 years, Acutaas Chemicals Limited has invested more than INR200 crores in electrolyte to start supplying it commercially.
    Show source
    And in the last 4 years, starting from 0 to now electrolyte, we are investing more than INR200 crores to make sure that we will start supplying in electrolyte commercially.
  • All capex at Acutaas Chemicals Limited's Unit 2 Ankleshwar was completed with commissioning of the last block.
    Show source
    Abhishek Patel: So all the capex at Unit 2 Ankleshwar has been completed with commissioning of last block.
  • Electrolyte additive capex at its Jhagadia site is on track and expected to be completed by Q3 FY '26.
    Show source
    Page 3 of 17 Acutaas Chemicals Limited October 17, 2025 To provide some additional update, the electrolyte additive capex at Jaghadia is progressing well and is expected to be completed by Q4 FY '26.

Demand and pricing

  • The company has more than 50% to 80% market share for most of its top products against any competitor.
    Show source
    Abhishek Patel: So as you know, for most of our top products, we have more than 50% to 80% kind of market share as against any of the competitor.

Segments

  • The company dispatched a couple of validation batches for new products during the last quarter.
    Show source
    And during the last quarter, we dispatched a couple of validation batches for new products, which mark important progress in scaling this vertical.
  • The company does not give a bifurcation of its Pharma business between CDMO and non-CDMO.
    Show source
    Related to your question of Pharma business split between CDMO and non-CDMO, we are not actually giving the bifurcation.
  • VC and FEC are Acutaas Chemicals Limited's two initial additive products, which it developed, marketed and already commercialized.
    Show source
    Abhishek Patel: First thing, let me give you the understanding that VC and FEC our 2 initial products which we developed, marketed and already commercialized.
  • The company has several other additives developed and commercialized, in addition to VC and FEC.
    Show source
    Apart from those 2 additive products, we Page 9 of 17 Acutaas Chemicals Limited October 17, 2025 have several other additives already developed and commercialized and full list of those chemicals are already available on our website.
  • Additives are for lithium-ion batteries, not sodium batteries.
    Show source
    Related to your question related to sodium batteries, all our additives are for lithium-ion batteries, lithium-ion batteries.

Everything else said on the call

Group structure

  • The company generated goodwill of around INR16 crores for this quarter from its investment in Indichem in Korea, after paying a premium for a noncontrolling stake.
    Show source
    So goodwill of around INR16 crores has been generated for this quarter for investment we have done in Indichem.
  • The company entered into a joint venture in South Korea named Indichem, where it is investing approximately KRW30 billion; Acutaas Chemicals Limited will hold a 75% stake, and its Korean partner will hold a 25% stake in exchange for technology and market access, and the facility will manufacture specialty chemicals used in chip production.
    Show source
    Abhishek Patel: In South Korean JV, we are the investment partner with 75% investment and 25% is with our Korean partner who will bring their technology, their market as well as the production capability.
  • The company has done Baba Fine Chem and is now doing a JV in Korea, where it is putting a new manufacturing site.
    Show source
    We have already done Baba Fine Chem and then now we are doing a JV in Korea, where we are putting a new manufacturing site.

People and governance

  • The company obtained KMPs in Baba and Indichem through partnership, with its Korean partner bringing technical and commercial background in the segment.
    Show source
    So automatically, by partnership, we got the KMP in Baba as well as in Indichem.

Other

  • Export-market receivables are generally on a 90-day basis and domestic receivables on a 120-day basis.
    Show source
    Bhavin Shah: So see, when we say for export market, our receivable is always on a 90-day side and domestic is on 120 days.
  • The company has said its receivables will average 105 to 110 days.
    Show source
    And we always said that it will be average 105 to 110 days.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Abhijit Akella: Okay. So the solar contribution is now fully in the base, is it? Or was it only partial for the quarter and we see the full impact in subsequent quarters?

    Answer, abhishek patel

    Abhishek Patel: It's completely on stream. Because the 5-megawatt project was commissioned in this quarter, it was partly accounted in this quarter for 5 megawatt out of the total 16 megawatt.

  2. Question

    Abhijit Akella: Got it. Just one further clarification on that margin topic. So Abhishek bhai, we have seen in the past that we used to enjoy 20% plus margins on the pharma side a few years back. And then there was some erosion that happened because of maybe Chinese competition and increasing raw material prices, et cetera. Now we have managed to claw it back. But just sort of wondering what gives us the confidence that the erosion that happened 2, 3 years back is not a risk factor to sort of be concerned about any further? Page 6 of 17 Acutaas Chemicals Limited October 17, 2025 Abhishek Patel: So it was a learning for us in 2022.

    Answer, abhishek patel

    And how we navigated through this process, that learning we convert into our SOPs to develop our business in going forward. And as we mentioned, we have taken several steps during that time and thereafter. But now because the pricing scenario got stable, it has now started showing into our bottom line from Q4 FY '24 onwards only. And this -- those are the learnings, which will definitely help us in future to have a maintain or drive the margin in future also.

  3. Question

    Abhijit Akella: Okay. Just one last thing for me before I get back in the queue. We are guiding to 25% revenue growth for this full year. In the first half, I believe we've done about 21%. So should we expect that the second half will be significantly better from a growth standpoint? And then also on the CDMO front, how much of the first half growth came from CDMO or what was its contribution? And where do you see it going in the second half? Will it be a very much heavier contribution in the second half from CDMO?

    Answer, abhishek patel

    Abhishek Patel: First of all, related to our revenue guidance for the full year, we are still very confident that we will deliver 25% growth rate for the full year after 21% growth in H1, considering whatever the pipeline we have in terms of our CDMO, our other Pharma Intermediate business as well as the newer verticals in chemical segment. Related to your question of Pharma business split between CDMO and non-CDMO, we are not actually giving the bifurcation. But in terms of growth, the higher growth is coming from the CDMO segment as it was earlier expected than the traditional business. And going forward also, that CDMO business will definitely have a better growth than the traditional Pharma Intermediates business.

  4. Question

    Nilesh G: Sure, sure. So this is regarding the receivables. So receivables in March '25 also were in the range of 29,000 lakh. And now this also -- this September 30, also number is in the same range. So what has led to this? If I compare this number with the FY '24 number, it is significantly higher.

    Answer, bhavin shah

    Bhavin Shah: So see, when we say for export market, our receivable is always on a 90-day side and domestic is on 120 days. And we always said that it will be average 105 to 110 days. With improved collection and our effort, we are able to bring it to 87 days for this quarter.

  5. Question

    Nilesh G: Okay. And secondly, on this -- our JV with -- you talked about last year in the month of June, you formed the planning to produce electrolyte. So any update on that?

    Answer, abhishek patel

    Abhishek Patel: That remains still status quo only, and it has not moved further from that level.

    Answer, abhishek patel

    Abhishek Patel: So as we mentioned during our commentary, the groundbreaking for this project was done in last month and project is expected to start in H2 FY '27. So from there onwards, the commercial revenue should start.

  6. Question

    Prayag Gandhi: Okay. And sir, going forward, we do expect like a lot of chemical companies are slowly shifting to CDMO space as well. What do you see the growth prospects over here as well? Because there will be eventually like other countries will also come into the picture. So where do we see the growth prospects for the next 3 to 5 years?

    Answer, abhishek patel

    Abhishek Patel: See, CDMO business, when we talk in CDMO business in pharma segment, is not a business which can come to anyone overnight. Of course, there is a lot of work available in the market and a lot of players are there in the market to grab those business. But that business is always a function of how you are complied with the quality system. Because originator or someone who is giving you the business for the outsourcing or the manufacturing of outsourcing in this industry, they would like to see the level of compliance related to QA, your consistency, relationship with that customer over the years. We got consistent supply, quality supply as well as the QA system in place. And lastly and not the least, the environment and the ESS compliance. These are all the factors which contribute or which gives us the confidence that we are one of the very good players to secure that business.

    Answer, abhishek patel

    And I would like to share one more insight that we now are EcoVadis Platinum certified company, which is only 1% of the companies over the world are into this territory. So this gives us the confidence that because of this, we are able to sustain -- in fact, get a good share of this business in the market.

    Answer, abhishek patel

    Abhishek Patel: First of all, I would like to make one thing very clear that both the business of semiconductor in India through Baba Fine Chem and in Korea through Indichem are completely different business verticals, no kind of connection. That is one thing. Related to products, which are going to get developed or manufactured in Indichem, actually, we have already mentioned that those are more value-added products than those traditional product in Baba Fine Chem. But over and above that, we will not be able to share more -- much detail on this product, which are going to manufacture there and our one customer, which is heraeus in Baba Fine Chem, we are committed to that customer fully to their product and the confidentiality of the product, and we are never going to get into their product line ever in that customer's business. It will be completely different business in Korea. Ajay: Okay, sir. Got it.

    Answer, abhishek patel

    Sir, another on the electrolyte side because we have mentioned the capacities of the 2 electrolyte additives, which we are going to manufacture. And like correct me if my understanding is incorrect but like maybe there are like 20, 30 another electrolyte additives in the market. So maybe in the overall scheme of things, like how big will be our both electrolyte VC and FEC in the additives market because these additives will again go into electrolyte, which will further go into making cells. So like if you can give maybe some color on the size of these 2 electrolyte additives and the overall scheme of things? And also, sir, just a follow-up on this because there are different technological advancements going on and which type of cell is going to emerge like maybe from LFP to NMC and now even sodium or zinc kind of batteries are getting traction. So my question is like are these additives which are going to manufacture? So when the type of cell changes, is it like the electrolyte additives also needs to change or the existing one would be capable enough to provide the stability between the like transfer of iron from cathode to anode.

    Answer, abhishek patel

    Abhishek Patel: First thing, let me give you the understanding that VC and FEC our 2 initial products which we developed, marketed and already commercialized. Apart from those 2 additive products, we Page 9 of 17 Acutaas Chemicals Limited October 17, 2025 have several other additives already developed and commercialized and full list of those chemicals are already available on our website. So those are based on our changing needs of the market and cater to the newer requirement of the customer. Related to your question related to sodium batteries, all our additives are for lithium-ion batteries, lithium-ion batteries. And related to your question of the size of this business, we have planned capacity of 2,000 metric ton VC and 2,000 metric ton FEC based on our signed contract with the customer and some demand. So we have full visibility of all the products, all the capacity, which we have planned. So based on that capacity requirement, you can estimate the size of this product.

    Answer, abhishek patel

    Ajay: No, sir, my question is again on the market, like the global electrolyte additives market would be like how big? And in that market, VC and FEC would be how much proposition like because VC as an additive for anode is like 30%, 40%. So I just wanted to know on the size.

    Answer, naresh patel

    Naresh Patel: Sorry to interrupt you here. Sir, here, I'm saying about Acutaas not with the global. And whatever we have done in installation of the capacity, we are supported with the agreement for long-term agreement for supply of VC and FEC. So that is what we have secured for ourselves. For further, if you can come to offline or you can do the research on that later on. Let's focus on the current Acutaas related stuff. Thank you very much for understanding.

    Answer, bhavin shah

    Bhavin Shah: Yes. So if you see the consolidated balance sheet, we have invested in Indichem in Korea with some premium. So noncontrolling stake, we paid some premium to a noncontrolling stake that is showing as a goodwill. So goodwill of around INR16 crores has been generated for this quarter for investment we have done in Indichem.

    Answer, bhavin shah

    Bhavin Shah: So if you see the INR19 crores, we have shown that in other income, that is exchange fluctuation, and that is form part of other income in P&L. Abhigyan Srivastav: Got it. And lastly, could you please explain the incidental charges that are paid towards investment, which are shown in the cash flow statement. So do these pertain to the financial investments or fixed assets?

    Answer, bhavin shah

    Bhavin Shah: This is towards incidental charges we have incurred and bank charges and other things towards the investment for Indichem.

    Answer, indichem srivastav

    Abhigyan Srivastav: Congratulations on the good set of numbers.

  7. Question

    So first question is on the capex front. So this year, we have spelled out INR250 crores. What is the number for FY '26? And out of this INR250 crores, how much is the growth capex and how much is maintenance? The other part is out of the growth capex, generally, what is the kind of asset turn that we look at and the peak potential revenue, how it is looked at? I mean, whether we look at 2 years, 3 years or 4 years? So if you could provide some details on this?

    Answer, abhishek patel

    Abhishek Patel: So out of INR250 crores capex plan for FY '26, INR40 crores we are expecting towards maintenance capex and rest is from the growth -- for the growth capex only. out of which around INR180 crores for the full year was planned for electrolyte additive capex and INR30 crores was planned for pilot plant capex. In terms of asset turn, we see generally around 2.5x is the asset turn we expect generally from all our capex going forward. This is what we expect from that. And around 3 years' time should be the good time by which it should scale up.

  8. Question

    Rohit Nagraj: Sure. And FY '27, any number as of now?

    Answer, abhishek patel

    Abhishek Patel: FY '27 for the growth expectation of till FY '28, we are already done with all our capex requirement, whatever projection we have done. And it will be more of a maintenance capex only.

  9. Question

    Rohit Nagraj: Sure. Second question is on the upcoming additives capacity. So once the capacity is commercialized, what will be the time taken to validate the products? Or since these are already being validated, we do not have to wait for the same?

    Answer, abhishek patel

    Abhishek Patel: No, it is already been validated from that site, and we will be able to quickly dispatch our material once capex gets completed.

  10. Question

    Rohit Nagraj: Sure. Just one clarification on the same. What is the kind of volume that we are looking from supplying in the domestic market and in the export market for the additives?

    Answer, abhishek patel

    Abhishek Patel: It's completely for export market only, no domestic supply from this plant.

    Answer, abhishek patel

    Abhishek Patel: If you see our past financial also, our first quarter was always low out of all 4 quarters. And sequentially, it grows every quarter-on-quarter till Q4 of every year. And we do not see any lumpiness in the business. It is CDMO business is based on the customer requirement, and we have a full visibility for this CDMO business for the full year as well as the projection for next years.

    Answer, abhishek patel

    Abhishek Patel: No, that we are actually not disclosing anywhere for the future businesses. Akshay: Okay. Fair enough. And Specialty Chemicals segment just grown by 7% year-on-year in first half -- sorry, in quarter 2. So can we expect higher year-on-year growth in half 2 of FY '26.

    Answer, abhishek patel

    Abhishek Patel: So we are guiding that this traditional spec chem business will remain in the territory of around 10% to 15% as a growth for the business. And we feel that it will remain in that territory only by the end of this financial year. Akshay: Okay. And lastly, sir, on the U.S. tariff impact. So what percentage of our revenue is coming from U.S.? And are there any impact of U.S. tariff in that?

Show 7 more questions
  1. Question

    Shreya Banthia: Yes. Do we have any visibility from the domestic battery manufacturers?

    Answer, abhishek patel

    Abhishek Patel: So let me just give you the background. This plant, what we have set up for 2,000 metric ton VC and FEC, that is based on the customer requirement, which is export customer. So we have not planned any capacity for domestic market catering.

  2. Question

    I hope I'm audible. Naresh bhai, I have just one fundamental question. So a few years ago, you were purely an advanced intermediate company. Now that you have multiple segments, CDMO, battery chemicals, semiconductor chemicals, each of them with -- all of them would have different set of challenges and very, very diverse. So I would like to understand a bit more on how the bandwidth for top management is placed, how we hired basically if we've hired some KMPs, manpower to run each of these businesses or anything else which you've done so that all the subsegments are on the right path. How do you see that kind of change over the last couple of years? And how will it change in the next couple

    Answer, naresh patel

    Naresh Patel: Okay. First of all, as you're tracking us since 5, 6 years, when we started electrolyte business, we enter into the electro business only because we want to expand our chemistry. We are a very strong chemistry-driven company. So basically, chemistry don't have an application only in pharma. So we want to expand our chemistry base out of pharma, and that's why we started acquiring Gujarat Organics and then we entered into the battery and then later on, we acquired Baba and now we enter into the semicon. So this is all to expand our strength into the production side and as well as the chemistry application. And two, if you see the last 5 years, management has introduced a lot of system digitalizations, KMPs are introduced time to time required for each segment.

    Answer, naresh patel

    So this is a part of the business cycle, and this is part of the business to grow from one state to another state. So when and when needed, we introduce the people as well as the system as well as the equipment to make sure that, that segment will grow. And in the last 4 years, starting from 0 to now electrolyte, we are investing more than INR200 crores to make sure that we will start supplying in electrolyte commercially. We have already done Baba Fine Chem and then now we are doing a JV in Korea, where we are putting a new manufacturing site. The KMP is coming from -- so the -- my Korean partner is himself, they are all our good technical background, commercial background in that segment. So automatically, by partnership, we got the KMP in Baba as well as in Indichem. So this is how either partnership or by recruiting, we got our KMP in the system.

    Answer, abhishek patel

    Abhishek Patel: Sorry, we will not be able to comment on how Chinese or what should be their EBITDA in this business. But at least what we know from -- since the development of these products from 2022, Page 13 of 17 Acutaas Chemicals Limited October 17, 2025 we made this product so robust in process. And at the current prevailing market price also, we are able to sustain the market and with the expected EBITDA margin. Raaj: All right. And sir, what would be our payback period?

    Answer, abhishek patel

    Abhishek Patel: For this -- any of the project, we expect the payback to be around 3 to 3.5 year kind of payback. Raaj: 3 to 3.5 years kind of payback. All right. Yes. And sir, on the South Korea JV, we are setting up a plant in Korea, right? So what exactly is our part in that JV?

    Answer, abhishek patel

    Abhishek Patel: In South Korean JV, we are the investment partner with 75% investment and 25% is with our Korean partner who will bring their technology, their market as well as the production capability.

    Answer, abhishek patel

    Abhishek Patel: As well as the supply of starting material. Raaj: Supply starting material. All right. And how much sales are we expecting from that Korean JV in FY '27?

    Answer, abhishek patel

    Abhishek Patel: No, no. It cannot go 100% in 1 year. It will take around 3 years' time to reach an optimum level of capacity. Raaj: And are we planning to invest more in that electrolyte additives going ahead?

    Answer, abhishek patel

    Abhishek Patel: As of now, we have not announced any capex around this business as of now. But as we mentioned, we have full visibility of this whole plant we have -- we are setting up for this business. And more business is expected considering the kind of business development going on. So we may announce additional capacity planning in future if needed.

    Answer, abhishek patel

    And all the margin improvement, whatever are done, these are more kind of permanent in the nature and as well as the function of the product mix. So based on that, we are confident that we will be able to sustain this margin level in future also.

  3. Question

    Ankit Mittal: electrolyte additives business.

    Answer, abhishek patel

    Abhishek Patel: No, no, electrolyte business definitely will not have such a high margins.

  4. Question

    Ankit Mittal: Okay. So it will be in the range of 15% to 20% then?

    Answer, abhishek patel

    Abhishek Patel: See, I think, Ekta Srivastava has to be abide by all the rules and regulation. And she is, I think, working within the purview or the boundary of the legal framework only. So maybe it was because of those.

  5. Question

    Vivek Gautam: I agreed, sir. But point is, out of -- one company out of 40, 50 companies, a small request, a small complaint only because everyone else is sharing then why is our company so hesitant to share it, sir. We are doing very good. We are having long-term point of view. We have seen the progress you have made. No harm in sharing this information also, sir.

    Answer, abhishek patel

    Abhishek Patel: Actually, I'm not aware of what was conversion going but at least I can assure you that whatever possible is there within the legal framework.

  6. Question

    Vivek Gautam: And sir, where is -- what are our differentiators versus competition and which is helping us out, sir? And you started out as 2 chemical engineers and have really evolved over the period, sir, and that's really great progress we have seen. We are very satisfied and happy and want to keep up with the good work. But you can highlight for the benefit of your investors, the differentiators, which we have and which can withstand the risk from the China and other places also, sir.

    Answer, abhishek patel

    Abhishek Patel: So as you know, for most of our top products, we have more than 50% to 80% kind of market share as against any of the competitor. So that shows our track record that we have been competing in the market for a long time.

    Answer, abhishek patel

    Abhishek Patel: So all the capex at Unit 2 Ankleshwar has been completed with commissioning of last block. But the capacity utilization will take its own time. And in next 2 years, it should reach to an optimum level. Margin expansion is not because of this commissioning of new block. As I mentioned, the margin expansion is a function of product mix as well as the operational efficiency as well as the cost improvement measure what we have done over the year. Tejas Sonawane: Okay. Understood.

  7. Question

    Nilesh G: Okay. And then what kind of growth you envisage over, let's say, 2, 3 years or the utilization to, let's say, optimum level? Since last 2, 3 years it has been around 40% to 50%.

    Answer, abhishek patel

    Abhishek Patel: So in this business, we are expecting growth in between 10% to 15% only going forward also.

Questions about this call

When was the Acutaas Chemicals Q2 FY26 earnings call transcript filed?
Acutaas Chemicals filed the transcript with the exchange on 24 Oct 2025. This page is built from that transcript.
What does this page list?
54 statements from the transcript across 9 topics, 39 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 17 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Acutaas Chemicals Q2 FY26 concall: what the company said · DalalOS